Are your peptide formulations degrading in liquid suspension before they reach the clinic? How do you ensure long-term stability without compromising the molecular structure of sensitive compounds?
The transition from research-grade peptide synthesis to stable, sterile clinical supply often hinges on one critical process: lyophilisation. Peptides in aqueous solutions are inherently unstable, vulnerable to chemical degradation pathways that can rapidly compromise batch integrity. Freeze-drying addresses this by removing the solvent matrix, arresting molecular mobility and extending shelf life. However, designing and scaling a lyophilisation cycle requires precise control over thermodynamics, formulation chemistry, and cleanroom environments.
TL;DR
| Concept | What it Means |
Hydrolysis Sublimation The phase transition of water directly from solid (ice) to gas (vapour) during primary drying, bypassing the liquid phase.[2] Primary Drying The longest phase of lyophilisation, operating under deep vacuum (e.g., 13 Pa) to remove unbound ice.[3] Secondary Drying The final phase involving elevated temperatures to desorb bound water molecules from the peptide matrix.[3] Residual Moisture The water remaining in the vial after lyophilisation; typically targeted at <3% to ensure long-term stability.[4] Karl Fischer Titration The gold-standard analytical method used to precisely measure residual moisture in lyophilised powders.[4] | |
The majority of research peptides available in the UK market are manufactured overseas, predominantly in China and India. This is not inherently problematic — there are reputable manufacturers in both countries — but it introduces supply chain complexity that UK-based manufacture avoids.
UK manufacture means that the entire supply chain — from raw material sourcing through synthesis, fill and finish, and quality testing — can be documented and audited within a single regulatory jurisdiction. For professional buyers who need to demonstrate due diligence, this traceability is a practical advantage.
UK manufacturers operate under MHRA oversight and are familiar with the regulatory expectations of UK professional buyers. This shared regulatory context simplifies documentation, reduces compliance risk, and ensures that quality standards are aligned with the expectations of the market being served.
Thanet Labs is a UK-based peptide manufacturing and supply facility working towards MHRA manufacturing authorisation. We are establishing supply relationships with research institutions, universities, and pharmaceutical development partners. Enquiries are welcome at this stage.
Overseas manufacture introduces variables that are harder to control: different pharmacopoeial standards, language barriers in documentation, and longer supply chains that increase the risk of temperature excursions and handling errors. UK manufacture reduces these variables and supports more consistent batch-to-batch quality.
